PHAR
Pharming Group N.V.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 27 ▲ Pharming Group received a positive opinion from the European Medicin…
- Sep 22 ▲ Pharming announced positive Phase II topline data for leniolisib in…
- Sep 25 ▲ Pharming announced FDA acceptance and Priority Review of its sNDA fo…
- Sep 29 ▼ Pharming Group announced that CEO Fabrice Chouraqui has stepped down…
- Oct 14 ▲ Pharming Group N.V. announced positive Phase II topline data for len…
- Oct 15 ▲ Short interest falls 33.2% to 13.4K
- Oct 18 Trial readout: Results Pending: Leniolisib (Phase 2), Completed 67d ago
- Oct 22 ▲ Pharming Group reported preliminary Q3 2026 total revenue of approxi…
- Oct 27 ▲ Pharming Group reported Q3 2026 total revenue of $117.6M, up 21% YoY…
- Oct 27 ▲ Pharming reported Q3 2026 total revenue of $117.6M, up 21% YoY and i…
- Oct 30 ▼ Short interest jumps 92.0% to 25.8K
- Nov 6 ▲ Pharming announced UK MHRA approval extending Joenja (leniolisib) to…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2026: 1 added (0 new), 0 trimmed or exited.
- AnalystsBULLISH
13 of 14 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate $0.107 → $0.060 over 90 days. 0 up, 1 down in 30 days.
- Short sellersBUILDING
Short interest +92.0% to 25.8K shares. 1.4 days to cover, ≈0.0% of shares.
- TrendUPTREND
15% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $87.0K |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | $4.2K |
| NewEdge Advisors, LLC | NEAR_EXIT | $2.6K |
| OSAIC HOLDINGS, INC. | NEAR_EXIT | $222.00 |
| MORGAN STANLEY | ADD | $191.2K |
| NewEdge Advisors, LLC | NEAR_EXIT | $35.8K |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | $6.7K |
| NewEdge Advisors, LLC | DOUBLED | $510.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analystsPrice is below the lowest target. Median implies +202%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 29, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Sep 22, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 14, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 3, 2026 | Canaccord Genuity MAINTAIN | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.06 | $0.02–$0.10 | -77.8% | $107.5M |
| Next Q | -$0.01 | -$0.01–-$0.01 | No data | $77.0M |
| Current FY | $0.26 | $0.04–$0.48 | -43.5% | $387.3M |
| Next FY | $0.18 | $0.04–$0.32 | -41.4% | $422.0M |
Short side
FINRA· Oct 30, 2026SecBot reports
15 filings · 3 press releases · 12 bullish · 1 bearish · 2 neutral- BULLISH 6-KNov 6, 2026
The U.K. MHRA approved an extension of Joenja (leniolisib) to include children aged 4-11 years…
Monitor NHS reimbursement and access timelines for the expanded pediatric indication, and watch for similar pediatric label expansions in other geographies (EU, US) that could further broaden the…
- BULLISH PRESS RELEASENov 6, 2026
Pharming announced UK MHRA approval extending Joenja (leniolisib) to children aged 4-11 weighing…
Monitor UK NHS reimbursement and access timelines for the pediatric indication; watch for similar pediatric label expansions in other geographies (US already approved for 4-11). The small patient…
- BULLISH 6-KOct 27, 2026
Pharming Group reported Q3 2026 total revenue of $117.6M, up 21% YoY and exceeding market…
The strong Q3 beat and guidance tightening confirm commercial momentum, especially Joenja's 58% revenue growth. Watch for CVID Phase II data in November 2026, which could significantly expand…
- BULLISH PRESS-RELEASEOct 27, 2026
Pharming reported Q3 2026 total revenue of $117.6M, up 21% YoY and in line with the $117.6M…
Monitor the November 2026 Phase II CVID data readout for leniolisib, which could expand the addressable patient population significantly beyond APDS. Also watch for the PDUFA decision on lower-dose…
All PHAR filing & press-release reports (18)
- 6-K reportNov 6, 2026
- PRESS-RELEASE reportNov 6, 2026
- 6-K reportOct 27, 2026
- PRESS-RELEASE reportOct 27, 2026
- 6-K reportOct 22, 2026
- 6-K reportOct 14, 2026
- 6-K reportSep 29, 2026
- PRESS-RELEASE reportSep 29, 2026
- 6-K reportSep 25, 2026
- PRESS-RELEASE reportSep 25, 2026
- 6-K reportSep 22, 2026
- 6-K reportSep 11, 2026
- 6-K reportAug 13, 2026
- 6-K reportJun 4, 2026
- 6-K reportMay 28, 2026
- 6-K reportMay 22, 2026
- 6-K reportApr 16, 2026
- 6-K reportMar 27, 2026